Hasil cek similarity "Integrated genomic analysis to identify druggable targets for pancreatic cancer"

Mugiyanto, Eko and Adikusuma, Wirawan and Irham, Lalu Muhammad and Chen Huang, Wan- and Chang, Wei-Chiao and Kuo, Chun-Nan (2022) Hasil cek similarity "Integrated genomic analysis to identify druggable targets for pancreatic cancer". Frontiers.

[thumbnail of HASIL CEK_genomic, pancreatic cancer, drug repurposing, fulvestrant, midostaurin (1).pdf] Text
HASIL CEK_genomic, pancreatic cancer, drug repurposing, fulvestrant, midostaurin (1).pdf

Download (2MB)


According to the National Comprehensive Cancer Network and the American
Society of Clinical Oncology, the standard treatment for pancreatic cancer (PC)
is gemcitabine and fluorouracil. Other chemotherapeutic agents have been
widely combined. However, drug resistance remains a huge challenge, leading
to the ineffectiveness of cancer therapy. Therefore, we are trying to discover
new treatments for PC by utilizing genomic information to identify PC´┐Żassociated genes as well as drug target genes for drug repurposing. Genomic
information from a public database, the cBio Cancer Genomics Portal, was
employed to retrieve the somatic mutation genes of PC. Five functional
annotations were applied to prioritize the PC risk genes: Kyoto Encyclopedia
of Genes and Genomes; biological process; knockout mouse; Gene List
Automatically Derived For You; and Gene Expression Omnibus Dataset.
DrugBank database was utilized to extract PC drug targets. To narrow down
the most promising drugs for PC, CMap Touchstone analysis was applied.
Finally, ClinicalTrials.gov and a literature review were used to screen the
potential drugs under clinical and preclinical investigation. Here, we
extracted 895 PC-associated genes according to the cBioPortal database
and prioritized them by using five functional annotations; 318 genes were
assigned as biological PC risk genes. Further, 216 genes were druggable
according to the DrugBank database. CMap Touchstone analysis indicated 13
candidate drugs for PC. Among those 13 drugs, 8 drugs are in the clinical trials,
2 drugs were supported by the preclinical studies, and 3 drugs are with no
evidence status for PC. Importantly, we found that midostaurin (targeted PRKA)
and fulvestrant (targeted ESR1) are promising candidate drugs for PC treatment
based on the genomic-driven drug repurposing pipelines. In short, integrated analysis using a genomic information database demonstrated the viability for
drug repurposing. We proposed two drugs (midostaurin and fulvestrant) as
promising drugs for PC.

Item Type: Artikel Umum
Subjects: R Medicine > RS Pharmacy and materia medica
Divisi / Prodi: Faculty of Pharmacy (Fakultas Farmasi) > S2-Master of Pharmacy (S2-Farmasi)
Depositing User: Lalu Muhammad Irham, M.Farm., Ph.D
Date Deposited: 07 Dec 2022 01:43
Last Modified: 07 Dec 2022 01:43
URI: http://eprints.uad.ac.id/id/eprint/37849

Actions (login required)

View Item View Item